Theraclone inks $18M antibody pact

Theraclone Sciences has struck a development deal worth up to $18 million with Japan's Zenyaku Kogyo. Theraclone will pocket an unspecified portion of that as an upfront payment for the alliance, which will focus on identifying antibodies that could be used to fight future pandemics. The deal comes just weeks after the Seattle-based biotech company revealed the discovery of two antibodies that can be used to fight HIV. Report